Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) open the trading on Wednesday, with great promise as it jumped 6.41% to $3.32, before settling in for the price of $3.12 at the close. Taking a more long-term approach, ZNTL posted a 52-week range of $2.83-$18.24.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -20.00%. Meanwhile, its Annual Earning per share during the time was -50.05%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 32.96%. This publicly-traded company’s shares outstanding now amounts to $70.77 million, simultaneously with a float of $61.39 million. The organization now has a market capitalization sitting at $236.09 million. At the time of writing, stock’s 50-day Moving Average stood at $3.33, while the 200-day Moving Average is $8.75.
Zentalis Pharmaceuticals Inc (ZNTL) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Zentalis Pharmaceuticals Inc’s current insider ownership accounts for 13.67%, in contrast to 97.54% institutional ownership. According to the most recent insider trade that took place on Oct 04 ’24, this organization’s Principal Accounting Officer sold 1,603 shares at the rate of 3.18, making the entire transaction reach 5,098 in total value, affecting insider ownership by 33,855. Preceding that transaction, on May 31 ’24, Company’s President, Interim CFO sold 9,597 for 11.98, making the whole transaction’s value amount to 114,972. This particular insider is now the holder of 633,680 in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
Zentalis Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 32.96% and is forecasted to reach -3.57 in the upcoming year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Let’s observe the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). It’s Quick Ratio in the last reported quarter now stands at 6.59. The Stock has managed to achieve an average true range (ATR) of 0.24. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.82.
In the same vein, ZNTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.75, a figure that is expected to reach -0.91 in the next quarter, and analysts are predicting that it will be -3.57 at the market close of one year from today.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
[Zentalis Pharmaceuticals Inc, ZNTL] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 82.46% While, its Average True Range was 0.21.
Raw Stochastic average of Zentalis Pharmaceuticals Inc (ZNTL) in the period of the previous 100 days is set at 4.97%, which indicates a major fall in contrast to 71.67% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 56.58% that was lower than 144.67% volatility it exhibited in the past 100-days period.
